| 生物活性 |
TAT-GluA2 3Y is a blood-brain barrier-permeable AMPA receptor inhibitory peptide that crosses the cell membrane via the HIV-1 TAT protein domain; it blocks AMPA receptor endocytosis, including internalization of GluA1/GluA2 subunits, by disrupting interactions with AP2, Brag2, and the Syt3-GluA2 complex, while also inhibiting long-term depression, and it blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic depression, and reduces cerebral ischemic volume, neurological deficits, and spatial memory deficits; moreover, it blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, attenuates the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP, making it useful for research on fear generalization, ischemic stroke, hypoxia, drug addiction, and opioid addiction. |
体内研究 (In Vivo) |
TAT-GluA2 3Y (4.32 μM/kg;腹腔注射;单次给药) 可阻断 NLRP3 敲除诱导的小鼠恐惧泛化,恢复海马 AMPA 受体 1 在 ser831 位点的磷酸化水平,并降低磷酸化 CaMKII 水平。 TAT-GluA2 3Y (5 mg/kg;腹腔注射;多次给药) 可破坏 Syt3 与 GluA2 的相互作用,提高 GluA2 的表面表达水平,抑制 CP-AMPAR 的形成,使大脑中动脉闭塞/再灌注 (MCAO/R) 诱导缺血性脑卒中的雄性 SD 大鼠的脑缺血体积减少约 40%-50%,改善神经功能,并增强其长期感觉运动及认知功能的恢复。 TAT-GluA2 3Y (1.5 nM/g;静脉注射;5 次 (每次右旋安非他明注射前 1 次,每 2 天 1 次)) 可阻断雄性 SD 大鼠中安非他明诱导的行为及神经化学敏化的诱导、维持与表达。 TAT-GluA2 3Y (15 pM;双侧微注射至腹侧被盖区 (VTA);共 5 次 (每次 d-苯丙胺注射前 1 次,每 2 天 1 次)) 可抑制雄性 SD 大鼠中苯丙胺诱导的行为敏化的维持与表达,但不抑制其诱导。 TAT-GluA2 3Y (按 1.5-2.25 nM/g 剂量静脉注射;每次吗啡条件化训练前 1 小时给药) 与吗啡在吗啡条件性位置偏爱 (CPP) 获得阶段联合给药,可促进偏好的快速消退,但不影响 CPP 的诱导、表达、维持或复燃。 TAT-GluA2 3Y (2.25 nM/g;静脉注射;每次食物条件化训练前 1 小时) 对大鼠食物诱导的条件位置偏好的诱导、消退及复建都无影响。
| Animal Model: |
C57BL/6J background NLRP3 knockout (male, 8-10 weeks old) |
| Dosage: |
4.32 μM/kg |
| Administration: |
i.p.; single dose |
| Result: |
Blocked the NLRP3 deprivation effect on fear generalization, as evidenced by a significant reduction in CS- freezing levels compared to untreated NLRP3 KO mice. Left basal and CS+ freezing levels comparable between treated and untreated groups. Recovered the hippocampal expression of phosphorylated AMPA receptor 1 at ser831. Decreased phosphorylated CaMKII levels. Left phosphorylated PKA levels unchanged. |
| Animal Model: |
Sprague-Dawley (male, 250-300 g, middle cerebral artery occlusion/reperfusion model) |
| Dosage: |
5 mg/kg |
| Administration: |
i.p.; multiple doses (1 h before MCAO/R, 1 h after MCAO/R, 1 h before each behavioral test on days 3, 5, 7, 14, 21, 22, 23, 24, 25, 26, 27 post-MCAO/R) |
| Result: |
Reduced Syt3-GluA2 co-immunoprecipitation levels in penumbral tissue by ~90% compared with saline controls at 6 h post-MCAO/R. Reduced ischemic volume to ~17% of total brain volume when administered 1 h before MCAO/R, compared with ~27% in scrambled peptide controls; reduced ischemic volume to ~20% when administered 1 h after MCAO/R. Reduced mNSS scores to ~5 when administered 1 h before MCAO/R, and ~7 when administered 1 h after MCAO/R, compared with ~12 in scrambled peptide controls at 24 h post-reperfusion. Increased surface GluA2 protein levels by ~40% in penumbral tissue at 6 h post-MCAO/R, compared with scrambled peptide controls, while intracellular GluA2 levels were reduced by ~40%. Reduced AMPAR-mediated excitatory postsynaptic current amplitude reduction by Naspm to ~20%, compared with ~50% reduction in scrambled peptide controls. Increased rotarod test latency to fall to ~220 s by day 21 post-MCAO/R, compared with ~150 s in scrambled peptide controls. Reduced adhesive removal test contact time to ~10 s, and removal time to ~15 s by day 21 post-MCAO/R, compared with ~30 s and ~40 s, respectively, in scrambled peptide controls. Reduced Morris water maze escape latency to ~20 s by day 26 post-MCAO/R, compared with ~30 s in scrambled peptide controls; increased platform crossings to ~3 times, compared with ~1 time in scrambled peptide controls. |
| Animal Model: |
Sprague-Dawley (male, 250-275 g, amphetamine-induced behavioural sensitization model) |
| Dosage: |
1.5 nM/g |
| Administration: |
i.v.; 5 times (once before each d-amphetamine injection every second day) |
| Result: |
Blocked the induction of locomotor sensitization. Attenuated d-amphetamine-induced dopamine efflux in the NAcc on day 9 to 278% of baseline, compared to 633% on day 1. Reduced the locomotor response to the d-amphetamine challenge significantly compared to vehicle or scrambled peptide control groups, with no significant difference from drug-naive rats. Blocked neurochemical sensitization, with d-amphetamine-induced dopamine efflux in the NAcc significantly lower than scrambled peptide control. |
| Animal Model: |
Sprague-Dawley (male, 250-275 g, amphetamine-induced behavioural sensitization model) |
| Dosage: |
15 pM |
| Administration: |
bilateral microinjection into VTA; 5 times (once before each d-amphetamine injection every second day) |
| Result: |
Did not affect the induction of locomotor sensitization, with significant increases in cumulative 30-min distance travelled from day 1 to day. Reduced the locomotor response to the d-amphetamine challenge significantly compared to vehicle or scrambled peptide control groups, blocking the maintenance and expression of behavioural sensitization. |
| Animal Model: |
Sprague-Dawley (male, 220-240 g at arrival, morphine-induced conditioned place preference model) |
| Dosage: |
1.5 nM/g; 2.25 nM/g |
| Administration: |
i.v.; 1 h before each morphine conditioning session |
| Result: |
Had no effect on induction, initial expression, or maintenance of morphine-induced CPP, with rats maintaining a significant preference for the morphine-associated compartment in bi-weekly tests over 8 weeks. Greatly facilitated extinction: rats treated with 1.5 nmol/g or 2.25 nmol/g failed to display a consistent preference for the morphine-paired compartment across 11 extinction days, whereas saline or scrambled peptide controls maintained preference until days 9 and 11 respectively. Had no effect on morphine-induced reinstatement of CPP, with all groups showing a significant preference for the morphine-associated compartment during retesting. |
| Animal Model: |
Sprague-Dawley (male, weight maintained at 90% of standard growth curve, food-induced conditioned place preference model) |
| Dosage: |
2.25 nM/g |
| Administration: |
i.v.; 1 h before each food conditioning session |
| Result: |
Had no effect on induction, extinction, or reinstatement of food-induced CPP. All groups displayed a significant preference for the food-associated compartment during initial testing, extinguished their preference within 15 days, and showed significant reinstatement after exposure to a Froot Loop, with no group differences detected via two-way ANOVA for any phase. |
|